No Data
No Data
10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Dru
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnol
Express News | BriaCell Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Safety And Efficacy Of Bria-OTS, BriaCell's Next Generation Immunotherapy
No Data
Mcsnacks H Tupack : Stock offering on file